The Genomics Revolution: Investing in CRISPR (w/ Cathie Wood)

TL;DR

The genomic revolution is set to transform healthcare by leveraging breakthrough therapies such as gene editing and DNA sequencing.

Transcript

I learned to pay a lot of attention to disruptive innovation when I was a young analyst. Or let's put it this way-- I wanted to be a young analyst. I was in economics. I started in the business in economics. But I knew I wanted to do equity research. And so I was at a wonderful firm, Jennison Associates at the time, who gave me the opportunity to d... Read More

Key Insights

• 💅 Breakthrough therapies, such as CAR-T therapy, show promising results in treating previously untreatable diseases.
• 💄 DNA sequencing costs are decreasing rapidly, making it more accessible for personalized medicine and disease identification.
• 🧡 Gene editing technologies like CRISPR-Cas9 have the potential to treat a wide range of diseases and offer significant revenue opportunities.
• 🖐️ China is heavily investing in genomics research and playing a crucial role in advancing the genomic revolution.
• 🤔 The genomic revolution has the potential to transform healthcare, but investor perception and short-term thinking hinder the correct valuation of stocks in this sector.
• 👶 The new FDA commissioner aims to accelerate the approval of breakthrough technologies to address diseases like cancer.

Questions & Answers

Q: What were some of the early breakthrough technologies in the healthcare sector that caught the analyst's attention?

The analyst mentions database publishing, DNA sequencing, and gene editing technologies as disruptive innovations that have the potential to transform healthcare.

Q: How does CRISPR technology work, and what are its potential applications?

CRISPR-Cas9 is a gene editing tool that can search and cut specific DNA sequences, allowing scientists to modify genes. Its applications include treating monogenic diseases, developing disease-resistant livestock and crops, and advancing agricultural practices.

Q: How is China contributing to the genomic revolution?

China has invested heavily in genomics research and has conducted the first CRISPR trials on human beings. They aim to sequence as many human genomes as possible and are accelerating their research in this field.

Q: How does the analyst view the investment opportunities in the genomic revolution?

The analyst believes that investing in companies with strong patent positions, such as Intellia, Editas, and CRISPR Therapeutics, is a good strategy. They also suggest a long-term investment horizon and emphasize that the genomic revolution presents a significant revenue opportunity.

Summary & Key Takeaways

• The genomic revolution analyst shares experiences of investing in disruptive innovation and exploring emerging technologies in the healthcare sector.

• Breakthrough therapies, such as CAR-T therapy, have shown promising results in treating aggressive non-Hodgkin's lymphoma, leading to complete remission rates of 50% after nine months.

• DNA sequencing and gene editing technologies, like CRISPR-Cas9, are paving the way for more precise diagnoses and potential cures for diseases by identifying genetic mutations and reprogramming them.